Citations

Clear

90 citation(s) found for "Midthun, D E".

Patient choice and uptake of Home-based rehabilitation with Health coaching versus Center-based pulmonary rehabilitation after a COPD-related hospitalization
Beenken, Madison, Hoult, Johanna, Midthun, William, Benzo, Maria

Mayo Clinic

Annals of the American Thoracic Society | November 11, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/annalsats/aaoag349 | PMID 43009181 Get It

Abstract Rationale Adherence to center-based pulmonary rehabilitation after a COPD-related hospitalization—which improves all outcomes, including survival—is only 3%. Home-based programs have been proposed as a more feasible option, but they are not systematically offered, and patient preference is unknown. Objectives and Methods This pragmatic randomized trial involving patients with COPD recently hospitalized for a COPD exacerbation, originally aimed to investigate the comparative effect two arms: The choice of a facilitated referral to a center-based outpatient pulmonary rehabilitation program or a home-based program versus a home-based program on adherence to post-hospitalization rehabilitation and disease-specific QoL measured by the Chronic Respiratory Questionnaire. The trial aimed to investigate the patient’s preference of home vs center-based rehabilitation in individuals randomized to the choice arm. Daily steps were measured by Actigraph ®. The asynchronous home-based program included weekly health coaching and daily monitoring of daily steps, symptoms, and a 20-minute daily flexibility-balance exercise routine. Results Of 1,906 patients approached, 294 (15%) were randomized and agreed to the rehabilitation options offered by the study arms (uptake); of those, 56% completed the 12-week intervention (adherence). Of the 145 randomized to the choice arm, only one patient chose center-based PR; therefore, both groups received the same intervention, and results are presented as a one-group (before–after) analysis. Compared with baseline, the home intervention significantly improved (p < 0.01) physical and emotional QoL (Chronic Respiratory Questionnaire) and increased daily steps beyond the minimal clinically important difference. Trajectory models adjusted for age, FEV1%, and mMRC (breathlessness) confirmed sustained improvements in QoL at 6 and 12 months from baseline. Conclusions When offered a choice of rehabilitation setting after a COPD-related hospital admission for an exacerbation, home-based rehabilitation is patients’ preferred option. Sustained quality-of-life improvements in 1 year may represent an opportunity to regain well-being and/or deliver primary palliative care. Our results may have important implications for clinical practice.
Five-year survival and complications of more than 300 articulating high-dose antibiotic spacers in two-stage revision total hip arthroplasties for infection
Weintraub, Matthew T. , Midthun, William R., Pagnano, Mark W., Taunton, Michael J. , Sierra, Rafael J. , Mabry, Tad M. , Perry, Kevin I. , Abdel, Matthew P. , Abdel, Matthew P , Sierra, Rafael J , Taunton, Michael J , Pagnano, Mark W. , Berry, Daniel J.

Mayo Clinic

The Bone & Joint Journal | September 1, 2026 | Volume: 108-B | Issue: 9 | Pages: 1104-1112

10.1302/0301-620x.108b9.bjj-2026-0551.r1 | PMID 42674571 Get It

Aims Two-stage exchange arthroplasty with an antibiotic-eluting cement spacer remains the predominant strategy in the USA for managing chronic periprosthetic joint infection (PJI) following total hip arthroplasty (THA). The aim of this study was to evaluate a commercially available, partially intraoperatively fabricated articulating high-dose antibiotic cement spacer, focusing on survival, complications, and patient-reported outcomes. Methods A total of 298 patients (302 THAs) underwent two-stage exchange arthroplasty for PJI using a specific articulating antibiotic spacer between August 2005 and May 2022. Patients with a previous failed two-stage exchange were excluded, although 121 THAs (302, 40%) had undergone previous PJI-related procedures. The mean age of the patients was 65 years (SD 11), the mean BMI was 32 kg/m 2 (SD 7), and 116 (38%) were female. Most patients were classified as McPherson host B (158; 52%) and limb grade 2 (165; 55%), and 265 (88%) met the 2011 Musculoskeletal Infection Society criteria. The mean follow-up was six years (2 to 16). Results At five years after reimplantation, survival free of reinfection, aseptic rerevision, any rerevision, or any reoperation were 89% (95% CI 85.2 to 93.1), 93% (95% CI 89.3 to 96.1), 86% (95% CI 81.3 to 90.3), and 80% (95% CI 74.7 to 84.9), respectively. Dislocation accounted for most aseptic rerevisions (15/20). McPherson host C (HR 3.7 (95% CI 1.4 to 9.6); p = 0.007) and limb grade 3 (HR 3.3 (95% CI 1.0 to 11.1); p = 0.049) were significantly associated with an increased risk of reinfection. The mean Harris Hip Score at the latest follow-up was 76 (29 to 100). A total of 17 patients underwent revision or removal of a spacer for concerns about persistent infection and two for dislocation of the spacer. Eight patients underwent a non-rerevision reoperation during the spacer interval for wound drainage (n = 5), dislocation of the spacer (n = 2), and perispacer fracture (n = 1). A total of 26 spacer-related complications were treated nonoperatively (15 perispacer fractures, 11 dislocations). Dislocation of the spacer was strongly associated with dislocation after reimplantation (HR 6.2 (95% CI 2.3 to 16.9); p < 0.001). Conclusion This commercially available, partially intraoperatively fabricated articulating spacer showed excellent reinfection-free five-year survival (89%). Spacer-related fracture and dislocation each occurred in 5% of patients. Dislocation of the spacer significantly increased the risk of dislocation following reimplantation, supporting the use of higher-stability bearings in these high-risk patients. Cite this article: Bone Joint J 2026;108-B(9):1104–1112.
EBRT and Interventions for Malignant Central Airway Obstruction: A False Dichotomy
Schwartz, Jacob, Ortiz, Gabriel, Anderson, Dagny , Kern, R, Mullon, John, Midthun, Dave, Ortiz, Gabriel, Kern, Ryan , Mullon, John J.

Mayo Clinic

Annals of the American Thoracic Society | May 21, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/annalsats/aaoag137 | PMID 42166730 Get It

A46-25 Buffalo Chest With a Twist
Kornafeld, A, Schwartz, J, Midthun, D E

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 18, 2026 | Volume: 212 | Issue: Supplement_1 | Pages: No page available

10.1093/ajrccm/aamag162.5946 Get It

Abstract A 71-year-old male with a history of progressive pulmonary fibrosis underwent bilateral lung transplantation via clamshell incision seven months prior to presenting with dyspnea and recurrent bilateral pleural effusions. His post-transplant course was complicated by lymphocytic myocarditis, leading to acute hypoxic respiratory failure and heart failure. Outpatient management with torsemide improved fluid status but was discontinued due to worsening renal function, resulting in effusion recurrence. Upon readmission, a right-sided 12 Fr pigtail thoracostomy tube was placed and left thoracentesis was done. Pleural fluid analysis revealed a serosanguineous, lymphocytic, exudative effusion on the right and a neutrophilic, transudative effusion on the left. Both had negative cytology and infectious studies. The left effusion initially seemed to be controlled. Persistent right-sided drainage prompted placement of a right indwelling tunneled pleural catheter (IPC). Pre-procedure imaging showed bilateral effusions, and ultrasound revealed a diminishing right effusion during setup, supporting interpleural communication. To aid IPC placement, one liter of lactated Ringer’s (LR) solution was infused into the right pleural space. Post-procedure imaging showed a large left-sided effusion and a small right effusion (Figure 1.), confirming buffalo chest physiology—fluid migration between pleural cavities due to the clamshell incision. Despite suction drainage and positional maneuvers, the left effusion persisted. Intrapleural administration of lytics via the right IPC failed to evacuate the left effusion. A subsequent left thoracentesis removed one liter of fluid, but recurrence necessitated placement of a left IPC one week later. Three weeks post-placement, the right IPC was removed, and continued drainage from the left IPC prevented recurrence of the right effusion. This case highlights the anatomical alterations following bilateral lung transplantation via clamshell incision, which can lead to atypical pleural fluid dynamics, including interpleural communication and buffalo chest physiology. Awareness of these changes is critical for effective management of pleural effusions in post-transplant patients. This abstract is funded by: None
C31-03 Rural-urban Trends in Tobacco Use, Lung Cancer Screening, and Smoking Cessation
Manful, A, Munro, H M, Mumma, M T, Decker, P A, Tranby, B N, Jiang, R, Bhattacharyya, O, Patten, C A, Midthun, D E, Aldrich, M C, Friedman, D L, Doubeni, C, Manful, Adoma, Mumma, Michael T. , Decker, P. A., Tranby, Brianna , Bhattacharyya, Oindrila , Patten, Christi A. , Aldrich, Melinda C. , Doubeni, Chyke A.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 18, 2026 | Volume: 212 | Issue: Supplement_1 | Pages: No page available

10.1093/ajrccm/aamag162.3903 Get It

Abstract Rationale Rural populations in the US experience a higher lung cancer burden compared to urban residents, potentially due to differences in risk factors and access to preventative care and early detection. We sought to characterize tobacco use, smoking cessation, and lung cancer screening patterns by rurality to identify modifiable gaps in the lung cancer care continuum. Methods We analyzed data from current and former smoking adults in the Southern Community Cohort Study, a large prospective cohort recruited from community health centers across 12 southeastern states. Participants aged 65-80 years with at least 9 months of Medicare Part A/B and less than 3 months of Part C coverage between 2014 and 2020 were included. Data were linked with the National Death Index and Medicare claims for outcome ascertainment. Rurality was defined using Rural-Urban Commuting Area (RUCA) codes. We compared demographic characteristics, smoking patterns, use of smoking cessation interventions, and receipt of low-dose computed tomography (LDCT) screening between rural and urban participants over time. Results Among 10,114 adults included (56% urban; 46% rural), 54% were female, 55% identified as Black/African American, about a third reported less than a high school education, and 45% lived in areas in the highest quartile of deprivation. Urban residents were of similar age (66 vs 67 years), and more likely to currently smoke (42% vs 35%), but had fewer baseline smoking pack-years (27 vs 30 pack-years) than rural residents. Approximately 2% died of lung cancer during follow-up. Using the USPSTF 2013 lung cancer screening criteria, 27% of urban and 26% of rural residents were eligible. This increased unevenly to 38% urban and 35% rural under the USPSTF 2021 criteria. LDCT uptake was low, increasing from 0% in 2014 to 6% in 2020 among screening-eligible participants. Use of cessation interventions was similarly low. Among current smoking participants, 7% received smoking cessation counseling, and 3% had a varenicline prescription. These patterns remained relatively stable over time, with no significant rural-urban differences in LDCT and cessation intervention use. Conclusion Despite modest differences in smoking prevalence and screening eligibility, we found comparable lung cancer mortality and similarly low utilization of LDCT and cessation interventions among rural and urban residents. Our findings suggest that, among people in lower socioeconomic groups, shared socioeconomic constraints may extend beyond the rural-urban divide. Further research is needed to understand how social determinants of health may be addressed to improve lung cancer outcomes across the screening continuum. This abstract is funded by: NIH
A31-09 Leveraging an Ehr-integrated Automated Program to Increase Lung Cancer Screening Uptake
Farah, W H, Bade, B, Midthun, D E, Christopherson, D R, Lunde, J, Zurob, A S, Harper, S, Zaied, A, Luedke, T, Diltz, J, Scrodin, M Dulohery, Zurob, Adel , Zaied, Ali, Luedke, Tabitha Crystal, Scrodin, M. Dulohery

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 18, 2026 | Volume: 212 | Issue: Supplement_1 | Pages: No page available

10.1093/ajrccm/aamag162.3625 Get It

Abstract Background Despite the reported benefits, lung cancer screening (LCS) uptake remains alarmingly low in comparison to other cancer screening programs. Objective To develop and evaluate an automated, electronic health record (EHR)-embedded LCS outreach program designed to increase screening uptake while minimizing workload for referring providers and schedulers. Methods We developed an automated outreach and referral program at two Mayo Clinic campuses (Rochester [RST] and northwest Wisconsin [NWW]) coupled with a streamlined virtual care delivery process. Eligible patients were identified based on the information in the EHR regarding US Preventive Services Task Force guidelines for screening and were contacted through either a patient portal message, letter, or both. Outreach included LCS educational materials and self-scheduling instructions for a telephone or video shared decision-making (SDM) visit. During the visit, a licensed care team member discussed the risks and benefits of a low dose computed tomography (LDCT) scan with patients who could choose to enroll in the Lung Cancer Screening Program or decline. Results During the study period, 8,845 eligible patients (RST: 2201, NWW: 6644) were contacted using automated portal messages, letters, or both. Among the RST cohort, 2,156 portal messages and 1,060 letters were distributed in comparison to 7,642 portal messages, 6,441 letters, and 618 text messages in the NWWI cohort. The study showed increase in shared decision-making visits completion and screenings for eligible patients across both groups. Portal engagement was higher among the RST group 75.4% than 55.8% in the NWWI group, as was digital brochure access (14.1% vs 6.5%). Scheduling for share-decision-making visits was noted to be higher among the RST group (22% vs 13.6%), though visit completion rates were similar across sites (12.6 vs 13.6%). A lower opt-out rate was noted among the RST group (12.6% vs. 14.3%). Collectively, both campuses demonstrated meaningful patient engagement. Conclusion The automated outreach program effectively increased lung cancer screening engagement and uptake for eligible patients without adding significant administrative burden on primary care providers and clinical staff. Observed differences in engagement between sites, as well as relatively low completion rates highlight the need for further investigation into contextual and operational factors influencing program performance. This abstract is funded by: none
Abstract 5045: Patterns of tobacco use, cessation interventions, and lung cancer screening in rural vs. urban areas over time; a 10-year retrospective cohort study
Tranby, Brianna , Decker, Paul A. , Jiang, Ruoxiang , Midthun, David E. , Aldrich, Melinda C. , Friedman, D. J., Manful, Adoma, Decker, Paul A. , Sakoda, Lori C. , Friedman, Debra, Bhattacharyya, Oindrila , Patten, Christi A. , Doubeni, Chyke A.

Mayo Clinic

Cancer Research | April 3, 2026 | Volume: 86 | Issue: 7_Supplement | Pages: 5045-5045

10.1158/1538-7445.am2026-5045 Get It

Abstract Introduction: Lung cancer rates differ across rural and urban areas, but few studies have evaluated rural-urban differences across the risk-screening continuum. We examined smoking, cessation interventions, and lung cancer screening patterns across the rural-urban continuum in a geographically defined area over 10 years. Materials and Methods: A retrospective cohort study (2014-2023) was conducted using clinical data from the Rochester Epidemiology Project, derived from healthcare encounters in a 27-county region of the midwestern United States. Patients ages 40-80 were included. We used Rural-Urban Commuting Area codes to assign residence as urban, rural, or highly rural. We examined yearly smoking prevalence, cessation intervention (pharmacotherapy, counseling), and low-dose computed tomography (LDCT) lung cancer screening. Results: Over the 10-year study period, the sample size ranged from 305,530 to 340,411 people annually with 36-38% urban, 56-57% rural, and 6-7% highly rural. Current smoking prevalence declined from 14 to 12% over the 10-year period (range=12-16%; p=0.06) and was consistently lower in urban areas (range=10-14%) than rural (range=12-17.0%) and highly rural areas (range=12-18%; p=&lt;0.001). Among individuals who currently smoked with no history of lung cancer, yearly smoking cessation intervention ranged from 16% to 23%, increasing over the 10-year period (p=&lt;0.001). Cessation medication (varenicline, bupropion, or nicotine replacement) prescription consistently increased overall over time but remained higher in urban than rural and highly rural areas (p=&lt;0.001). Cessation counseling rates also increased overall over time and were similar between urban and rural areas and lower in highly rural areas (p=&lt;0.001). Among people who had ever-smoked aged 50-80 years with no diagnosis of lung cancer, LDCT screening increased from 0.0% to 3.1% over the study period. Increases were higher in urban areas (0.0-3.6%) and similar in rural and highly rural areas (0.0-2.8% and 0.0-2.9%, respectively; p=&lt;0.001). Among people who currently smoked, LDCT screening also increased over the study period (0.0-6.4%), with higher increases in urban (0.1-8.0%) than rural (0.0-5.7%) or highly rural (0.1-6.1%) areas (p=&lt;0.001). After the new screening guidelines in 2021, rates in all areas increased year-on-year. Conclusion: In this cohort, we found that smoking prevalence, cessation interventions, and lung cancer screening improved from 2014-2023 across the rural-urban continuum. Unfortunately, smoking prevalence remained higher and cessation interventions and screening rates lower in rural compared to urban areas. The persistent patterns underscore the need for strategies to overcome barriers for rural residents and improve lung cancer prevention and early detection in all areas. Citation Format: Brianna Tranby, Paul A. Decker, Jiang Ruoxiang, David Midthun, Lori C. Sakoda, Melinda C. Aldrich, Debra Friedman, Adoma Manful, Oindrila Bhattacharyya, Christi Patten, Chyke A. Doubeni. Patterns of tobacco use, cessation interventions, and lung cancer screening in rural vs. urban areas over time; a 10-year retrospective cohort study [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 5045.
Beyond Physical Frailty—the Value of Lifestyle and Social Frailty Factors to Predict Mortality and Hospitalization in COPD
Midthun, William R., Novotny, Paul J. , Benzo, Roberto P.

Mayo Clinic

Journal of Cardiopulmonary Rehabilitation and Prevention | November 26, 2025 | Volume: 46 | Issue: 1 | Pages: 28-34

10.1097/hcr.0000000000000991 | PMID 41295267 Get It

Purpose: Lifestyle and social frailty factors are a new focus in the multidimensional concept of frailty, as recent reports have found strong associations with negative health outcomes. We searched for specific social and lifestyle frailty factors independently associated with 5-year survival and the risk of hospitalization in patients with severe chronic obstructive pulmonary disease (COPD). Methods: We retrospectively analyzed questionnaire data from the National Emphysema Treatment Trial (NETT) and identified items related to the published definition of social frailty. Classification and Regression Tree, a machine learning method, was used to select variables most strongly associated with survival time or hospitalizations beyond 12 months of NETT study enrollment. Kaplan-Meier curves, log-rank tests, and Cox proportional hazards models were used to determine relationships between social/lifestyle variables and hospitalization and survival. Results: Four social and lifestyle frailty factors were significantly related to survival (impaired lifting, bathing and dressing, in-store shopping, and loneliness). Two social and lifestyle frailty factors were significantly related to risk of hospitalization (emotional distress and difficulty performing work or activities). A combination of 6 questions provided clinical phenotypes that were robustly and independently associated with mortality risk and hospitalization with hazard ratios that ranged from 2.4 to 11.2 and 2.2 to 3.5 for survival and hospitalization, respectively, after adjustment for age, sex, disease severity, and physical frailty. Conclusion: Lifestyle and social frailty factors that could be easily identified in practice may represent a novel approach to a multidimensional frailty assessment to predict survival and hospitalization in patients with severe COPD.
The Efficacy of Repeat Talc Pleurodesis After Initial Failure
Wireko, F.W. , Ahmed, Adil , JAIMES, GABRIEL E ORTIZ, Mullon, John J., Midthun, David E. , Anderson, D.K., SCHIAVO, DANTE N, Edell, Eric S. , ORTIZ-JAIMES, GABRIEL E, Nelson, David R. , Kern, Ryan

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A4082-A4082

10.1164/ajrccm.2025.211.abstracts.a4082 Get It

Abstract Rational: Talc pleurodesis is an effective intervention for preventing recurrent pleural effusions and pneumothoraces, particularly in non-surgical candidates. Due to its efficacy and safety, it is recommended as the most effective sclerosant for pleurodesis. However, in some cases, the initial pleurodesis fails, necessitating a repeat procedure. The efficacy of repeat talc pleurodesis after an initial failure is an area that requires further exploration. This study explores the safety and efficacy of repeat talc pleurodesis among patients who did not respond to the initial intervention. Methods: This retrospective study analyzed hospitalized patients who underwent 4g talc slurry pleurodesis from 2019 to 2024, focusing on demographics, comorbidities, initial pleurodesis failure, and recurrence rates. Pleurodesis failure was identified by lung sliding, recurrent effusion, or pneumothorax during the same hospitalization. The primary outcome was recurrence post-discharge, assessed by pleural effusion or pneumothorax within 180 days post-repeat pleurodesis. Results: This study included 94 patients (52.1% male, 47.9% female) with a mean age of 67.6. Among them, 79 (84%) received a single 4g dose of talc, while 15 (16%) received multiple 4g talc doses for initial pleurodesis. Recurrence occurred in 20 (25.3%) of the single-dose group and 1 (6.7%) of the multiple-dose group within 180 days, though the difference was not statistically significant (p=0.112). Recurrence-free rates were 93.6% at 30 days, 85.1% at 90 days, and 77.7% at 180 days. Of the 20 patients with recurrence after a single 4g dose of talc, 8 (40%) underwent repeat pleurodesis, with only one recurrence requiring surgical intervention. Additionally, there was no recurrence after repeat talc pleurodesis in the one patient with recurrence after receiving multiple 4g talc doses for initial pleurodesis. No associations were found between recurrence rates and factors like gender (p=0.213) or comorbidities (emphysema, COPD, lung malignancy). Chest pain was a common complaint, but no cases of respiratory distress were reported post-pleurodesis. Conclusion: The efficacy of initial talc pleurodesis (77.7%-93.6%) in this cohort aligns with existing literature. Multiple-dose talc pleurodesis effectively prevented recurrence in 93.3% of patients, with no reported respiratory distress. Additionally, repeat talc pleurodesis was successful in 87.5% of those with recurrence after an initial single 4g dose. These findings support multiple-dose talc pleurodesis and repeat talc pleurodesis as safe and effective options for preventing recurrence post-initial failure and post-repeat talc pleurodesis, respectively. Although no significant recurrence predictors were identified, future research could focus on patient-specific factors to enhance treatment selection and optimize outcomes.
Paclitaxel-coated Balloon Dilation in Recurrent Airway Stenosis
ORTIZ-JAIMES, GABRIEL E, Mullon, John J., Nelson, Darlene R. , Reisenauer, Janani , Midthun, David E. , Edell, Eric S. , Anderson, D.K., Kern, R., Vargas-Brochero, Maria J. , Kern, Ryan

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A1147-A1147

10.1164/ajrccm.2025.211.abstracts.a1147 Get It

Abstract Rationale: Airway-stenosing disease is a significant clinical problem in multiple populations. While the immediate endoscopic and clinical response to bronchoscopic interventions are high, rates of clinically significant recurrence are elevated, and often require multiple and frequent reinterventions. Newer strategies to prevent recurrence of central and proximal airway stenosis are needed. Methods: Retrospective review of bronchoscopic balloon bronchoplasties performed at the Mayo Clinic utilizing paclitaxel coated balloons (PCB) in 2023-2024 for recurrent airway stenosis. IN.PACT Admiral and AV balloons (sizes 5-12 mm, 3.5 mcg/mm2 paclitaxel dose) were used with an inflation time of 2-3 minutes. Procedural success was defined as &lt;50% airway stenosis or resolution of the procedural indication. Reintervention was considered only if a therapeutic bronchoscopy was subsequently required to address the same lesion treated with PCB. Only patients with follow-ups &gt;90 days were included in the reintervention inter-procedural time analysis. Results: Thirty-three procedures were performed in 18 patients. Seventeen (51%) for lung transplantation-associated stenosis (29% anastomotic/perianastomotic, 76% lobar and segmental stenoses), 8 (24%) for granulomatous polyangiitis-associated stenosis, 3 for postintubation tracheal stenosis and 2 for chemical/pill injury. Eighteen cases (54%) utilized an additional dilation modality (12 non-coated balloon dilation, 4 rigid dilation), 5 spray cryotherapy, 6 other ablative therapies (4 CO2-laser, 2 electrocautery cuts), and 6 received an airway stent during the same procedure. 57% percent of interventions occurred in the lobar, 27% mainstem/bronchus intermedius, 9% tracheal, 7% segmental airways. Thirty-one (93%) cases had a satisfactory initial endoscopic result. The median number of bronchoscopic therapeutic interventions required before the use pf PCB was 5 (IQR 2.5-11.5), which significantly decreased to 0.1 (IQR 0-1, range 0-9) after PCB (p &lt;0.001). The reintervention-free survival significantly increased after PCB dilation from a median 35 days (IQR 28.7-80.5) to 132 days (IQR 64-197; p=0.004). Twenty-one cases required subsequent bronchoscopies, sixteen (76%) of which demonstrated improvement in lesion severity when compared to the results of prior interventions. Only 16 (48%) required therapeutically addressing the same lesion. Only 2 minor complications occurred (6%, self-limited bleeding and unplanned admission), none related to paclitaxel use. Six-month mortality was 3% from an unrelated cause. Conclusions: The locoregional antiproliferative effects of paclitaxel show promise in preventing recurrence, minimizing the need for repeat procedures, and extending intervals between interventions in patients with recurrent, predominantly benign airway stenosis. Its use is feasible, safe, and future research is warranted, particularly comparing PCB with the currently available strategies.